State of the Globe - Reframing the Role of Novel β-lactam/β-lactamase Inhibitors in the Era of Antimicrobial Resistance

β-lactam antibiotics have served as the backbone of antimicrobial therapy for decades. They act by targeting bacterial cell wall synthesis. The bacterial cell wall is composed of peptidoglycan, consisting of long glycan chains cross-linked by peptide bridges through the action of transglycosidases and transpeptidases.[1] Penicillin-binding proteins (PBPs) facilitate this cross-linking process. β-lactam antibiotics bind to PBPs, inhibiting their activity and preventing the synthesis of new peptidoglycan, ultimately leading to disruption of the cell wall and bacterial lysis. These properties have made β-lactams reliable agents for both empirical and targeted therapies, owing to their broad-spectrum activity, favorable pharmacokinetic–pharmacodynamic profiles, and well-established safety. However, inappropriate prescribing, excessive antimicrobial exposure, and in some regions, over-the-counter availability have accelerated the emergence of resistance, particularly among Gram-negative bacilli. Enterobacterales and Pseudomonas aeruginosa remain leading causes of severe healthcare-associated infections, especially in critically ill and immunocompromised patients. Resistance mechanisms include the production of extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, and carbapenemases, as well as nonenzymatic mechanisms such as porin loss or alteration, which reduces antimicrobial penetration. Additionally, overexpression of multidrug efflux pumps actively expels antibiotics, lowering intracellular drug concentrations. Additional mechanisms, including target-site alterations and biofilm formation, may further contribute to therapeutic failure and persistent infection [Figure 1].[1] Globally, antimicrobial resistance is recognized as one of the most serious public health threats of the 21st century, posing substantial risks to patient outcomes and infection control efforts.[2]Figure 1: Different mechanisms of Beta-lactum resistance in different bacteriaβ-lactamase enzymes hydrolyze the β-lactam ring, rendering antibiotics ineffective. Among the most clinically important are ESBLs, AmpC β-lactamases, and carbapenemases such as KPC, NDM, VIM, IMP, and OXA-type enzymes, which confer resistance to a broad spectrum of β-lactam antibiotics, including third-generation cephalosporins and carbapenems. The increasing global prevalence of these enzymes has created significant therapeutic challenges, particularly in severe community- and healthcare-acquired infections. In response, newer β-lactamase inhibitors structurally distinct from traditional agents such as clavulanate, sulbactam, and tazobactam have been developed. This has led to the emergence of novel β-lactam/β-lactamase inhibitor (NβL/βLI) combinations, providing promising therapeutic options against multidrug-resistant (MDR) pathogens.[3-5] Against this backdrop, the systematic review and meta-analysis by Elkholi et al. provides a timely synthesis of randomized evidence evaluating NβL/βLIs for infections caused by Enterobacterales and P. aeruginosa.[6] The authors analyzed 22 randomized controlled trials comprising more than 7600 participants and compared agents such as ceftazidime–avibactam, ceftolozane–tazobactam, meropenem–vaborbactam, imipenem–cilastatin–relebactam, cefepime–enmetazobactam, cefepime–taniborbactam, and aztreonam–avibactam against best available therapy (BAT). Their findings are clinically relevant and provide important evidence supporting the use of these agents in appropriately selected patients: NβL/βLIs demonstrated efficacy comparable to BAT with respect to clinical cure and mortality, while providing enhanced microbiological eradication, particularly in complicated urinary tract infections (cUTIs) and infections due to MDR organisms. The significance of these findings extends beyond noninferiority. This work emerges at a critical point in antimicrobial stewardship, where clinicians must balance the need for broad-spectrum empirical therapy with the imperative to preserve carbapenem efficacy. The results support the growing role of NβL/βLI combinations as potential carbapenem-sparing agents without compromising clinical outcomes. The most pronounced benefit was observed in cUTIs, where NβL/βLIs were associated with improved clinical and microbiological cure rates. This finding is biologically plausible, as many of these agents achieve high urinary concentrations, enhancing antibacterial activity in the urinary tract. Furthermore, cUTIs frequently involve ESBL-producing Enterobacterales, for which agents such as ceftazidime–avibactam and meropenem–vaborbactam have demonstrated robust activity. These results reinforce current IDSA recommendations that prioritize the use of newer β-lactam/β-lactamase inhibitor combinations for selected carbapenem-resistant Enterobacterales infections, particularly when the resistance mechanism is susceptible to inhibition by these agents. Importantly, the activity of currently available NβL/βLI combinations remains variable against metallo-β-lactamase-producing organisms, particularly those harboring NDM, VIM, or IMP enzymes. This limitation underscores the continued need for mechanism-directed therapy and rapid molecular diagnostics to guide antimicrobial selection. An important observation is the discordance between microbiological eradication and overall clinical cure. This underscores a key principle in infectious diseases therapeutics: microbiological superiority does not necessarily translate into large differences in clinical outcomes, particularly when comparator regimens are already highly effective. In contemporary randomized trials, demonstrating superiority in mortality or clinical cure is inherently challenging due to high baseline cure rates and multifactorial determinants of patient outcomes. Thus, maintaining clinical efficacy while improving pathogen eradication and reducing carbapenem exposure may represent meaningful therapeutic progress.[7] Despite these encouraging findings, several limitations warrant consideration. A substantial proportion of the pooled population consisted of patients with cUTIs, whereas complicated intra-abdominal infections (cIAIs) and hospital-acquired or ventilator-associated pneumonia (HAP/VAP) were less well represented. Sensitivity analyses further suggested that much of the observed microbiological benefit was driven by cUTI studies, highlighting the potential site-specific nature of the treatment effect. This imbalance may have contributed to the overall positive findings, particularly with respect to microbiological outcomes. Indeed, subgroup analyses showed less consistent benefit in cIAI and HAP/VAP populations. Pulmonary infections remain particularly challenging due to factors such as limited antibiotic penetration into lung tissue, altered host immunity, and biofilm-associated resistance. The relatively modest benefit observed in HAP/VAP also reflects the complex resistance mechanisms of P. aeruginosa, including AmpC overexpression, OprD porin loss, efflux pump upregulation, and structural mutations in cephalosporinases. These mechanisms highlight a critical reality: no antimicrobial agent remains indefinitely protected from resistance evolution. The long-term effectiveness of NβL/βLIs will therefore depend on their judicious use within comprehensive antimicrobial stewardship frameworks. Importantly, the analysis demonstrated no increase in mortality or serious adverse events with NβL/βLI therapy, supporting the safety and tolerability of these agents in clinical practice. However, most included studies were industry-sponsored, introducing the potential for funding bias despite rigorous methodological assessment. Additionally, variability in definitions of microbiological cure and MDR across studies may contribute to heterogeneity. The pooling of different β-lactam/β-lactamase inhibitor combinations, each with distinct pharmacologic and resistance profiles, while practical, may obscure important agent-specific differences. Several key questions remain. Future studies should include head-to-head comparisons between different NβL/βLI agents to better define optimal therapy for specific resistance phenotypes. Additional data are needed in bloodstream infections, immunocompromised populations, and severe pneumonia, where clinical uncertainty persists. Furthermore, real-world effectiveness studies integrating rapid molecular diagnostics and antimicrobial stewardship interventions may better reflect contemporary practice. Nevertheless, the expanding role of these agents must be accompanied by robust antimicrobial stewardship. The history of antimicrobial therapy consistently demonstrates that bacterial adaptation inevitably follows antibiotic innovation. The challenge ahead lies not only in developing new antimicrobial agents but also in preserving the effectiveness of existing therapies through stewardship, surveillance, and mechanism-directed treatment strategies. Research quality and ethics statement This article is an editorial that synthesizes previously published literature and does not report on any new empirical studies.